Current evidence on the relationship between three polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis von Zhang, Jian, Qiu, Li-Xin, Wang, Zhong-Hua, Leaw, Shiang-Jiin, Wang, Bi-Yun, Wang, Jia-Lei, Cao, Zhi-Gang, Gao, Jia-Li, Hu, Xi-Chun

Volltext

The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects von Zhang, Jian, Qiu, Li-Xin, Leaw, Shiang-Jiin, Hu, Xi-Chun, Chang, Jian-Hua

Volltext

Clinical features and treatment outcomes of 14 cases of primary ovarian non-Hodgkin’s lymphoma: a single-center experience von Zhao, Xiao-Ying, Hong, Xiao-Nan, Cao, Jun-Ning, Leaw, Shiang-Jiin, Guo, Ye, Li, Zi-Ting, Chang, Jian-Hua

Volltext

RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 von Wang, Jie, Lu, Shun, Yu, Xinmin, Hu, Yanping, Sun, Yuping, Wang, Zhijie, Zhao, Jun, Yu, Yan, Hu, Chunhong, Yang, Kunyu, Feng, Guosheng, Ying, Kejing, Zhuang, Wu, Zhou, Jianying, Wu, Jingxun, Leaw, Shiang Jiin, Zhang, Jing, Lin, Xiao, Yang, Nong

Volltext

P3.02b-099 Pharmacokinetics of Osimertinib (AZD9291) in Chinese Patients with Advanced NSCLC: A Phase I Study: Topic: EGFR RES von Cao, Junning, Chang, Jianhua, Zhang, Clara, Leaw, Shiang Jiin, Wang, Jia, Cantarini, Mireille, Zhang, Li

Volltext

P3.02b-099 Pharmacokinetics of Osimertinib (AZD9291) in Chinese Patients with Advanced NSCLC: A Phase I Study von Cao, Junning, Chang, Jianhua, Zhang, Clara, Leaw, Shiang Jiin, Wang, Jia, Cantarini, Mireille, Zhang, Li

Volltext

Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy von Leaw, Shiang Jiin, Yen, Chia Jui, Huang, Wen Tsung, Chen, Tsai Yun, Su, Wu Chou, Tsao, Chao Jung

Volltext